TY - JOUR T1 - Prophylaxis with tetracyclines in ARDS: Potential therapy for COVID-19-induced ARDS? JF - medRxiv DO - 10.1101/2020.07.22.20154542 SP - 2020.07.22.20154542 AU - James D. Byrne AU - Rameen Shakur AU - Joy E. Collins AU - Sarah Becker AU - Cameron C. Young AU - Hannah Boyce AU - Giovanni Traverso Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/28/2020.07.22.20154542.abstract N2 - There is an immediate need for therapies related to coronavirus disease 2019 (COVID-19), especially candidate drugs that possess anti-inflammatory and immunomodulatory effects with low toxicity profiles. We hypothesized the application of pleiotropic tetracyclines as potential therapeutic candidates. Here, we present a retrospective multi-institutional cohort study evaluating ventilatory status in patients who had taken a tetracycline antibiotic within a year prior to diagnosis of acute respiratory distress syndrome (ARDS). The primary outcomes were the need for mechanical ventilation and duration of mechanical ventilation. The secondary outcome was the duration of intensive care unit (ICU) stay. Data was evaluated using logistic regression and treatment effects regression models. Minocycline or doxycycline treatment within a year prior to ARDS diagnosis was associated with a 75% reduced likelihood for mechanical ventilation during hospital stay. Furthermore, tetracycline antibiotic therapy corresponded to significant reductions in duration of mechanical ventilation and ICU stay in ARDS patients. These data suggest tetracyclines may provide prophylactic benefit in reducing ventilatory support for ARDS patients and support further evaluation in a randomized prospective trial.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJ.D.B. was supported by the Prostate Cancer Foundation Young Investigator Award and DoD Prostate Cancer Foundation Early Investigator Award, and Hope Funds for Cancer Research Postdoctoral Fellowship. R.S. is funded by an independent Jansons Foundation grant. G.T. was supported in part by the Department of Mechanical Engineering, MIT and Brigham and Women Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Appropriate institutional review board approval (#2020P001110) was granted by the Partners review board. Informed consent was waived due to the retrospective nature of the research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files. ER -